Phase Ib Clinical Trial of ACT201 Injection in Participants With Treatment-Naïve Chronic Hepatitis B
A Multicenter, Randomized, Open-Label Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of ACT201 Injection in Participants With Treatment-Naïve Chronic Hepatitis B(CHB)
This is a multicenter, randomized, open-label, parallel-controlled phase Ib clinical trial, which aims to evaluate the safety and preliminary efficacy of ACT201 injection combined with standard-of-care therapy (PegIFNα, NAs) in treatment-naive participants with chronic hepatitis B. A total of 60 treatment-naive participants with chronic hepatitis B are planned to be enrolled and randomized Treatment Group 1, Treatment Group 2, Treatment Group 3 or Treatment Group 4 for treatment.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Minghui Li, Ph.D
- Telefonnummer: 010-84322284
- E-mail: Wuhm2000@sina.com
Studiesteder
-
-
-
Beijing, Kina
- Beijing Ditan Hospital, Capital Medical University
-
Kontakt:
- Minghui Li
-
Xi'an, Kina
- The Second Affiliated Hospital of Xi'an Jiaotong University
-
Kontakt:
- Shuangsuo Dang
-
Xiamen, Kina
- The First Affiliated Hospital of Xiamen University
-
Kontakt:
- Xiulan Xue
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Voluntarily participate in this trial and sign the informed consent form;
- Aged 18 to 65 years (inclusive), male or female;
- Body mass index (BMI) between 18 and 32 kg/m² (inclusive);
- HBsAg-positive or HBV DNA-positive for at least 6 months, or previous liver biopsy showing chronic HBV infection, or HBsAg-positive and anti-HBc IgM-negative at screening;
- No prior treatment with nucleos(t)ide analogues or interferons for chronic hepatitis B within 6 months before screening;
- HBsAg, HBeAg, HBV DNA and liver function indicators meet the protocol requirements;
- Willing to use effective contraception and have no plan for pregnancy, sperm donation or oocyte donation.
Exclusion Criteria:
- Subjects with recent major trauma or major surgery, or those scheduled to undergo surgery;
- Presence of clinically significant uncontrolled abnormalities or other severe diseases other than chronic HBV infection;
- History of other liver diseases;
- History of liver cirrhosis;
- Imaging suggestive of a suspected malignant hepatic lesion;
- Past or current evidence of hepatic decompensation;
- History of extrahepatic diseases potentially associated with HBV immune status;
- Other diseases associated with vasculitis;
- Infections (other than HBV) requiring systemic antiviral or antibacterial therapy at screening;
- History of malignancy;
- Prior solid organ or bone marrow transplantation;
- Presence or history of severe psychiatric disorders;
- Severe retinopathy or other serious ophthalmic diseases;
- Prior or current use of prohibited medications;
- Concomitant hematological diseases;
- Abnormal laboratory findings;
- Abnormal QTcF interval;
- History of allergy;
- Lactating female subjects or those with a positive serum pregnancy test at screening;
- Participation in another clinical trial, or failure to complete the washout period specified in the protocol prior to this trial;
- Any other condition that, in the opinion of the investigator, renders the subject unsuitable for participation in this trial.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Gruppe 2
|
Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration shall follow the study protocol Once daily, orally, until the end of the trial |
|
Eksperimentel: Gruppe 1
|
Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration shall follow the study protocol Once daily, orally, until the end of the trial |
|
Eksperimentel: Gruppe 3
|
Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration shall follow the study protocol Once daily, orally, until the end of the trial |
|
Eksperimentel: Gruppe 4
|
Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration shall follow the study protocol Once daily, orally, until the end of the trial |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Safety: number of participants with adverse event (AE), serious adverse events (SAE) and clinically significant examination results. Assessments include vital signs, physical examinations, laboratory tests, and 12-lead electrocardiograms (ECGs)
Tidsramme: throughout the full study period,an average of 38 weeks
|
throughout the full study period,an average of 38 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
HBsAg, HBsAb and HBV DNA levels and changes from baseline
Tidsramme: throughout the full study period,an average of 38 weeks
|
throughout the full study period,an average of 38 weeks
|
|
HBsAg seroclearance rate
Tidsramme: throughout the full study period,an average of 38 weeks
|
throughout the full study period,an average of 38 weeks
|
|
HBsAg seroconversion rate
Tidsramme: throughout the full study period,an average of 38 weeks
|
throughout the full study period,an average of 38 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Minghui Li, Ph.D, Beijing Ditan Hospital
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- ACT201-4-1-002
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .